Literature DB >> 2263244

[Clinical results of selective treatment for flail chest].

T Kasai1, K Tajimi, K Kobayashi.   

Abstract

A better understanding in pathophysiology of flail chest has brought an evolution to the principles of it's management. The methods of stabilization changed from surgical to pneumatic measures and now, a concept of conservative treatment is recognized. Adhering to our protocol for flail chest, which essentially limits mechanical ventilation, we have prospectively treated 36 patients since 1981. The patient were divided into two groups according to their need for mechanical ventilation. There were 16 patients (44.4%) in a group treated in conservative manner and with no mechanical ventilation (Group A). There were 20 patients (55.6%) in a group treated by mechanical ventilation (Group B). Group A had 6.2% incidence of pneumonia, 3.6 days average stay in ICU and mortality rate of 0%. Group B had 75% pneumonia, 22.5 days average in ICU and 15% mortality. Group B patients required respiratory support for 14 days average, which was not reduced by surgical stabilization. Restrictive pulmonary disturbance in group A was milder than that of group B, and this again was not affected by surgical stabilization. We conclude that 40% of flail chest are controllable without mechanical ventilation and that the result of this conservative therapy is superior to any other treatments.

Entities:  

Mesh:

Year:  1990        PMID: 2263244

Source DB:  PubMed          Journal:  Nihon Geka Gakkai Zasshi        ISSN: 0301-4894


  2 in total

1.  [Repair of intrathoracic visceral damage using video-assisted thoracoscopic surgery for blunt chest trauma and rib fixation at the site of mini-thoracotomy].

Authors:  T Tagawa; S Itoh; S Ide; K Tanaka; K Yoshida; H Ohe
Journal:  Jpn J Thorac Cardiovasc Surg       Date:  1998-01

2.  The benefits of early rib fixation for clinical outcomes of flail chest patients in intensive care unit.

Authors:  İsmail Ağababaoğlu; Hasan Ersöz
Journal:  Turk Gogus Kalp Damar Cerrahisi Derg       Date:  2020-04-22       Impact factor: 0.332

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.